Buy Ilumya (tildrakizumab)

What is Ilumya (tildrakizumab) for?

Ilumya (tildrakizumab) is an interleukin (IL)-23 antagonist (immunosuppressant) indicated for the treatment of adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).^[1]

It is available as a single-dose prefilled syringe, containing 100 mg/mL tildrakizumab.^[1]

How does Ilumya (tildrakizumab) work?

tildrakizumab is a human monoclonal antibody, a type of protein, that binds to the cytokines interleukin (IL)-23. Cytokines play a role in signaling in a cell, especially in inflammation. Dysregulated production of and IL-23 were found to be very important in the development of specific diseases, such as psoriasis.^[2]

By binding to IL-23, tildrakizumab will block their action, and thereby slow down inflammation.^[1,2]

Where has Ilumya (tildrakizumab) been approved?

Ilumya (tildrakizumab) was approved by:

• The Food and Drug Administration (FDA), USA on March 20, 2018.^[3]
• The European Medicines Agency (EMA), Europe on September 17, 2018 under the brand name Ilumetri.^[4]

Ilumya (tildrakizumab) has been granted Orphan Drug designation by the FDA for treatment of type 1 diabetes mellitus patients with residual beta-cell function in November 2010, for treatment of pediatric Crohn’s disease in May 2016, for treatment of pediatric ulcerative colitis in February 2017, and for treatment of pediatric systemic lupus erythematosus in July 2017.^[14]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Ilumya (tildrakizumab) taken?

The standard dosage is:^[1]

• Starting dose: 100 mg at Weeks 0, 4
• Every twelve weeks (3 months) thereafter

Complete information about Ilumya dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Ilumya (tildrakizumab)?

Common adverse reactions

The most common adverse reactions (≥1% of patients) listed in the prescribing information include:^[1]

• upper respiratory infections
• Injection site reactions
• Diarrhea

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Increased risk of infections (bacterial, fungal, and viral)

Use in a specific population

It is not known whether Ilumya (tildrakizumab) can cause fetal harm when given to a pregnant woman; it is advised to avoid pregnancies and breastfeeding.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [EMA]: Ilumya (tildrakizumab) [PDF] Almirall, Mar 2018

2. Targeting IL-23 in psoriasis: current perspectives
Fotiadou C, Psoriasis (Auckl.), Jan 4, 2018

3. FDA Approves ILUMYA (tildrakizumab-asmn) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
Press release, Mar 2018

4. Ilumetri
EMA product page, Sep 2018